Reproductive and hormonal factors, family history, and breast cancer according to the hormonal receptor status

Rosato, Valentina; Bosetti, Cristina; Negri, Eva; Talamini, Renato; Maso, Luigino Dal; Malvezzi, Matteo; Falcini, Fabio; Montella, Maurizio; Vecchia, Carlo La

doi:10.1097/cej.0b013e3283639f7a

Cited by 27 publications

(22 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second, when we consider that there are several BC subtypes and that some of them are less likely to be influenced by reproductive factors, it is possible that our results could be the reflection of a different BC subtype. For example, it has been shown that the increased BC risk with an older age at FFTP is more frequent in hormone‐dependent BC, which is more prevalent among Caucasian women . If we consider the context of African women with an overrepresentation of hormone receptor–negative BC and the fact that this subtype is known to be more prevalent among younger women with a younger age at FFTP or with high parity and if we hypothesize that high parity confers an overall short‐term exposure to estrogen, younger women with high parity might then be protected against hormone‐dependent BC but not against hormone receptor–negative BC.…”

Section: Discussionmentioning

confidence: 99%

“…For example, it has been shown that the increased BC risk with an older age at FFTP is more frequent in hormonedependent BC, which is more prevalent among Caucasian women. [23][24][25][26][27] If we consider the context of African women with an overrepresentation of hormone receptor-negative Figure 2. Odds ratios and 95% confidence intervals for developing breast cancer among parous women according to the number of full-term pregnancies versus nulliparous women.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Breast cancer risk after full‐term pregnancies among African women from Nigeria, Cameroon, and Uganda

Sighoko

Ogundiran

Ademola

et al. 2015

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe breast cancer (BC) risk profiles of African women differ significantly from those of women of European ancestry. African women are younger at the age of onset and tend to have high parity. The purpose of this study was to examine the relationship between full‐term pregnancy (FTP) and the risk of BC.METHODSA case‐control study was conducted among 1995 women with invasive BC and 2631 controls in Nigeria, Cameroon, and Uganda. Odds ratios (ORs) for individual ages at FTP according to the time since delivery were calculated and adjusted for confounders. A fitted spline model was used to assess the impact of the number of pregnancies on BC risk.RESULTSIn comparison with a nulliparous woman, a parous woman with her first FTP at 20 years showed an OR of 0.76 (95% confidence interval [CI], 0.57‐0.99) for developing BC in the following 5 years. Ten years later, this risk was 0.76 (95% CI, 0.58‐0.99) and 0.76 (95% CI, 0.58‐0.98) for women aged 25 and 30 years, respectively. Similarly, a parous woman with 1 pregnancy had an OR of 0.69 (95% CI, 0.49‐0.96), whereas the OR was 0.66 (95% CI, 0.48‐0.91) with 2 or 5 pregnancies and 0.67 (95% CI, 0.47‐0.94) with 6 pregnancies in comparison with nulliparous women.CONCLUSIONSIn contrast to studies in women of European ancestry, this study showed no transient increase in the risk of developing BC after FTP among African women. Further studies are needed to examine the impact of reproductive factors on early‐onset BC in African women. Cancer 2015;121:2237–2243. © 2015 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Breast cancer risk after full‐term pregnancies among African women from Nigeria, Cameroon, and Uganda

Sighoko

Ogundiran

Ademola

et al. 2015

Cancer

View full text Add to dashboard Cite

show abstract

“…the estrogen receptor (ER) and the progesterone receptor (PR) [24–31]. It is only in recent years that studies have been conducted incorporating data on human epidermal growth factor receptor 2 (HER2) status [32–38], with a few having included other additional molecular markers [3, 34, 39–44]. However, most studies so far have not been able to run molecular expression studies on a large scale.…”

Section: Introductionmentioning

confidence: 99%

Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program

et al. 2017

View full text Add to dashboard Cite

BackgroundBreast cancer comprises several molecular subtypes with different prognoses and possibly different etiology. Reproductive and hormonal factors are associated with breast cancer overall, and with luminal subtypes, but the associations with other subtypes are unclear. We used data from a national screening program to conduct a large nested case-control study.MethodsWe conducted a nested case-control study on participants in the Norwegian Breast Cancer Screening Program in 2006 − 2014. There was information on estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) for 4748 cases of breast cancer. Breast cancer subtypes were defined as luminal A-like (ER+ PR+ HER2-), luminal B-like (ER+ PR- HER2- or ER+ PR+/PR-HER2+), HER2-positive (ER- PR- HER2+) and triple-negative (ER- PR- HER2-). Conditional logistic regression was used to estimate odds ratios (ORs) of breast cancer associated with age at first birth, number of pregnancies, oral contraceptive use, intrauterine devices and menopausal hormone therapy. Analyses were adjusted for age, body mass index, education, age at menarche, number of pregnancies and menopausal status.ResultsNumber of pregnancies was inversely associated with relative risk of luminal-like breast cancers (p-trend ≤0.02), and although not statistically significant, with HER2-positive (OR = 0.60, 95% CI 0.31–1.19) and triple-negative cancer (OR = 0.70, 95% CI 0.41–1.21). Women who had ≥4 pregnancies were at >40% lower risk of luminal-like and HER2-positive cancers than women who had never been pregnant. However, there was a larger discrepancy between tumor subtypes with menopausal hormone use. Women who used estrogen and progesterone therapy (EPT) had almost threefold increased risk of luminal A-like cancer (OR = 2.92, 95% CI 2.36–3.62) compared to never-users, but were not at elevated risk of HER2-positive (OR = 0.88, 95% CI 0.33–2.30) or triple-negative (OR = 0.92, 95% CI 0.43 − 1.98) subtypes.ConclusionsReproductive factors were to some extent associated with all subtypes; the strongest trends were with luminal-like subtypes. Hormone therapy use was strongly associated with risk of luminal-like breast cancer, and less so with risk of HER2-positive or triple-negative cancer. There are clearly some, but possibly limited, etiologic differences between subtypes, with the greatest contrast between luminal A-like and triple-negative subtypes.Trial registrationNot applicable.

show abstract

“…All chemicals and solvents were purchased from commercial vendors and were used without further purification. (2)(3)(4)(5)(6)(7)(8)(9)(10). A mixture of monopotassium salt (3.55 mmol) and of the appropriate phenacyl chloride (3.55 mmol) was refluxed under stirring in ethanol (30 mL) for 3 h. After cooling, the precipitate was collected, washed with ethanol, dried, and recrystallized from a mixture of ethanol/dioxane with the exception of compound (recrystallization solvent: ethanol).…”

Section: Synthetic Proceduresmentioning

confidence: 99%

“…This represents about 12% of all new cancer cases and 25% of all cancers in women. A number of risk factors have been identified, such as a strong family history of breast cancer, weight gain, smoke, menopausal hormone therapy (MHT), and alcohol consumption [4][5][6]. However, the causes of the disease are not yet fully understood.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Experimental Validation of New Designed Heterocyclic Compounds with Antiproliferative Activity versus Breast Cancer Cell Lines MCF-7 and MDA-MB-231

Barresi

Bonaccorso

Cristaldi

et al. 2017

Journal of Chemistry

View full text Add to dashboard Cite

Recent drug discovery efforts are highly focused towards identification, design, and synthesis of small molecules as anticancer agents. With this aim, we recently designed and synthesized novel compounds with high efficacy and specificity for the treatment of breast tumors. Based on the obtained results, we constructed a Volsurf+ (VS+) model using a dataset of 59 compounds able to predict the in vitro antitumor activity against MCF-7 cancer cell line for new derivatives. In the present paper, in order to further verify the robustness of this model, we report the results of the projection of more than 150 known molecules and 9 newly synthesized compounds. We predict their activity versus MCF-7 cell line and experimentally verify the in silico results for some promising chosen molecules in two human breast cell lines, MCF-7 and MDA-MB-231.

show abstract

Reproductive and hormonal factors, family history, and breast cancer according to the hormonal receptor status

Cited by 27 publications

References 29 publications

Breast cancer risk after full‐term pregnancies among African women from Nigeria, Cameroon, and Uganda

Breast cancer risk after full‐term pregnancies among African women from Nigeria, Cameroon, and Uganda

Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program

Synthesis and Experimental Validation of New Designed Heterocyclic Compounds with Antiproliferative Activity versus Breast Cancer Cell Lines MCF-7 and MDA-MB-231

Contact Info

Product

Resources

About